Patients with advanced, recurrent, or metastatic gynecological cancers who have exhausted other treatment options are potential candidates for nivolumab. However, the decision to use this drug should be made based on a thorough evaluation by a multidisciplinary team, considering factors such as the patient's overall health, tumor characteristics, and previous treatment history.
